{"organizations": [], "uuid": "96c4350a6ae3428b5f84158c7bb10c47227c7950", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/novartis-pharmaceuticals/novartis-says-kymriah-receives-second-u-s-fda-approval-idUSL3N1S842O", "country": "US", "domain_rank": 408, "title": "Novartis says Kymriah receives second U.S. FDA approval", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-02T05:37:00.000+03:00", "replies_count": 0, "uuid": "96c4350a6ae3428b5f84158c7bb10c47227c7950"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/novartis-pharmaceuticals/novartis-says-kymriah-receives-second-u-s-fda-approval-idUSL3N1S842O", "ord_in_thread": 0, "title": "Novartis says Kymriah receives second U.S. FDA approval", "locations": [], "entities": {"persons": [{"name": "kymriah", "sentiment": "negative"}, {"name": "liz barrett", "sentiment": "none"}, {"name": "jonathan oatis", "sentiment": "none"}, {"name": "ishita chigilli palli", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "kymriah", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "u.s. fda", "sentiment": "negative"}, {"name": "s. food and drug administration", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "novartis oncology", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Swiss drugmaker Novartis said on Tuesday it received a second approval from the U.S. Food and Drug Administration (FDA) for a second form of the blood cancer drug Kymriah.\nThe company said it received FDA approval to treat adult patients with relapsed or refractory large B-cell lymphoma.\n“Today’s FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development,” said Liz Barrett, chief executive of Novartis Oncology.\nKymriah, a chimeric antigen receptor T cell (CAR-T) therapy, in August won FDA approval for treatment of acute lymphoblastic leukemia in patients up to 25 years old. (Reporting by Ishita Chigilli Palli in Bengaluru; editing by Jonathan Oatis)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T05:37:00.000+03:00", "crawled": "2018-05-02T07:18:03.007+03:00", "highlightTitle": ""}